ANTHEMAnthem Biosciences Limited
Pharma · Biotechnology · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ANTHEM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • ROE: 19.5%
- • ROCE: 22.8%
- • Debt/Equity: 0.02
- • RSI: 63
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • ROE: 19.5%
- • ROCE: 22.8%
- • Debt/Equity: 0.02
- • RSI: 63
Bear case
- • Revenue growth: -22.6% YoY
- • Profit growth: -12.8% YoY
- • MACD: bearish
- • Volume: 1.0x 20-day average
Key risks
- • Revenue growth: -22.6% YoY
- • Profit growth: -12.8% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹29.09). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.